This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sahin, F. Articles by Torbenson, M. Search for Related Content PubMed PubMed Citation Articles by Sahin, F. Articles by Torbenson, M.

mTOR and P70 S6 Kinase Expression in Primary Liver Neoplasms

¹ Department of Pathology, The Johns Hopkins Hospital, Baltimore, Maryland; and ² Center for Advanced Diagnostics, Ameripath, Inc., Orlando, Florida

Purpose: mTOR and P70 S6 kinase (S6K) play a key role in regulating protein translation. The role of mTOR and S6K in hepatocellular carcinoma has not been investigated, but this pathway is of particular interest because an effective inhibitor, rapamycin, is available. This study was undertaken to determine the prevalence and clinicopathological correlates of mTOR pathway activation in hepatocellular carcinoma and to determine whether rapamycin inhibits the pathway in cell culture.

Experimental Design: Total and phosphorylated mTOR and S6K protein expression were studied by immunohistochemistry in hepatocellular carcinomas (n = 73), fibrolamellar carcinomas (n = 13), and hepatic adenomas (n = 15). Results were correlated with tumor growth pattern as defined by the WHO (trabecular, pseudoglandular/acinar, compact, and scirrhous), tumor size, Ki-67 proliferation index, and the modified Edmondson nuclear grade, which has a scale of 1 to 4. HepG2 and Hep3B cell lines were treated with rapamycin to see the effect on proliferation and S6K phosphorylation.

Results: Increased expression of total mTOR was seen in 5% of hepatocellular carcinoma, whereas overexpression of phospho-mTOR was evident in 15% of hepatocellular carcinoma. Phospho-mTOR positivity correlated with increased expression of total S6K, which was found in 45% of cases. Total S6K overexpression was positively correlated with tumor nuclear grade, inversely with tumor size, and was unassociated with the proliferation index or WHO growth pattern. Rapamycin treatment of HepG2 and Hep3B cell lines markedly inhibited cell proliferation and reduced S6K phosphorylation in both cell lines.

Conclusions: The mTOR pathway is activated in a subset of hepatocellular carcinoma. Rapamycin can inhibit proliferation of neoplastic hepatocytes in cell culture.

This article has been cited by other articles:

				T. Fujishita, K. Aoki, H. A. Lane, M. Aoki, and M. M. Taketo Inhibition of the mTORC1 pathway suppresses intestinal polyp formation and reduces mortality in Apc{Delta}716 mice PNAS, September 9, 2008; 105(36): 13544 - 13549. [Abstract] [Full Text] [PDF]

				Y. L. Pon, H. Y. Zhou, A. N.Y. Cheung, H. Y.S. Ngan, and A. S.T. Wong p70 S6 Kinase Promotes Epithelial to Mesenchymal Transition through Snail Induction in Ovarian Cancer Cells Cancer Res., August 15, 2008; 68(16): 6524 - 6532. [Abstract] [Full Text] [PDF]

				Z. Wang, J. Zhou, J. Fan, S.-J. Qiu, Y. Yu, X.-W. Huang, and Z.-Y. Tang Effect of Rapamycin Alone and in Combination with Sorafenib in an Orthotopic Model of Human Hepatocellular Carcinoma Clin. Cancer Res., August 15, 2008; 14(16): 5124 - 5130. [Abstract] [Full Text] [PDF]

				J Boone, F J W T. Kate, G J A Offerhaus, P J van Diest, I H M B. Rinkes, and R van Hillegersberg mTOR in squamous cell carcinoma of the oesophagus: a potential target for molecular therapy? J. Clin. Pathol., August 1, 2008; 61(8): 909 - 913. [Abstract] [Full Text] [PDF]

				M. B. Thomas, J. P. O'Beirne, J. Furuse, A. T. C. Chan, G. Abou-Alfa, and P. Johnson Systemic Therapy for Hepatocellular Carcinoma: Cytotoxic Chemotherapy, Targeted Therapy and Immunotherapy Ann. Surg. Oncol., April 1, 2008; 15(4): 1008 - 1014. [Abstract] [Full Text] [PDF]

				H. Huynh, P. K.H. Chow, and K.-C. Soo AZD6244 and doxorubicin induce growth suppression and apoptosis in mouse models of hepatocellular carcinoma Mol. Cancer Ther., September 1, 2007; 6(9): 2468 - 2476. [Abstract] [Full Text] [PDF]

				R. Parent, D. Kolippakkam, G. Booth, and L. Beretta Mammalian Target of Rapamycin Activation Impairs Hepatocytic Differentiation and Targets Genes Moderating Lipid Homeostasis and Hepatocellular Growth Cancer Res., May 1, 2007; 67(9): 4337 - 4345. [Abstract] [Full Text] [PDF]

				F. Vega, L. J. Medeiros, V. Leventaki, C. Atwell, J. H. Cho-Vega, L. Tian, F.-X. Claret, and G. Z. Rassidakis Activation of Mammalian Target of Rapamycin Signaling Pathway Contributes to Tumor Cell Survival in Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma. Cancer Res., July 1, 2006; 66(13): 6589 - 6597. [Abstract] [Full Text] [PDF]

				S. Han, F. R. Khuri, and J. Roman Fibronectin Stimulates Non-Small Cell Lung Carcinoma Cell Growth through Activation of Akt/Mammalian Target of Rapamycin/S6 Kinase and Inactivation of LKB1/AMP-Activated Protein Kinase Signal Pathways Cancer Res., January 1, 2006; 66(1): 315 - 323. [Abstract] [Full Text] [PDF]